205 related articles for article (PubMed ID: 25245578)
1. Real-world outcomes of hemostatic matrices in cardiac surgery.
Tackett SM; Calcaterra D; Magee G; Lattouf OM
J Cardiothorac Vasc Anesth; 2014 Dec; 28(6):1558-65. PubMed ID: 25245578
[TBL] [Abstract][Full Text] [Related]
2. Observational evaluation of outcomes and resource utilization from hemostatic matrices in spine surgery.
Price JS; Tackett S; Patel V
J Med Econ; 2015; 18(10):777-86. PubMed ID: 25934148
[TBL] [Abstract][Full Text] [Related]
3. Cost-consequence analysis of different active flowable hemostatic matrices in cardiac surgical procedures.
Makhija D; Rock M; Xiong Y; Epstein JD; Arnold MR; Lattouf OM; Calcaterra D
J Med Econ; 2017 Jun; 20(6):565-573. PubMed ID: 28097913
[TBL] [Abstract][Full Text] [Related]
4. Cost-consequence analysis of two different active flowable hemostatic matrices in spine surgery patients.
Makhija D; Rock M; Ikeme S; Kuntze E; Epstein JD; Nicholson G; Price JS; Patel V
J Med Econ; 2017 Jun; 20(6):606-613. PubMed ID: 28287015
[TBL] [Abstract][Full Text] [Related]
5. Similar patient outcomes yet different hospital costs between flowable hemostatic agents.
David G; Lim S; Gunnarsson C; Kocharian R; Roy S
J Med Econ; 2015; 18(9):735-45. PubMed ID: 25907200
[TBL] [Abstract][Full Text] [Related]
6. Real-world economic and clinical outcomes associated with current hemostatic matrix use in spinal surgery.
Danker W; Kelkar SS; Marston XL; Aggarwal J; Johnston SS
J Comp Eff Res; 2022 Dec; 11(17):1231-1240. PubMed ID: 36306241
[TBL] [Abstract][Full Text] [Related]
7. Floseal only versus in combination in spine surgery: a comparative, retrospective hospital database evaluation of clinical and healthcare resource outcomes.
Ramirez MG; Deutsch H; Khanna N; Cheatem D; Yang D; Kuntze E
Hosp Pract (1995); 2018 Oct; 46(4):189-196. PubMed ID: 29986148
[TBL] [Abstract][Full Text] [Related]
8. Prospective, randomized, controlled clinical trial of a novel matrix hemostatic sealant in children undergoing adenoidectomy.
Mathiasen RA; Cruz RM
Otolaryngol Head Neck Surg; 2004 Nov; 131(5):601-5. PubMed ID: 15523433
[TBL] [Abstract][Full Text] [Related]
9. Hospital economic impact from hemostatic matrix usage in cardiac surgery.
Tackett SM; Sugarman R; Kreuwel HT; Alvarez P; Nasso G
J Med Econ; 2014 Sep; 17(9):670-6. PubMed ID: 24927164
[TBL] [Abstract][Full Text] [Related]
10. Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery.
Nasso G; Piancone F; Bonifazi R; Romano V; Visicchio G; De Filippo CM; Impiombato B; Fiore F; Bartolomucci F; Alessandrini F; Speziale G
Ann Thorac Surg; 2009 Nov; 88(5):1520-6. PubMed ID: 19853105
[TBL] [Abstract][Full Text] [Related]
11. Real-World Clinical and Economic Outcomes Associated with Surgiflo
Danker W; Aggarwal J; Kelkar SS; Marston XL; Gao X; Johnston SS
Clinicoecon Outcomes Res; 2022; 14():129-138. PubMed ID: 35299991
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, Security, and Manageability of Gelified Hemostatic Matrix in Bleeding Control during Thoracic and Lumbar Spine Surgery: FloSeal versus Surgiflo.
Landi A; Gregori F; Marotta N; Delfini R
J Neurol Surg A Cent Eur Neurosurg; 2016 Mar; 77(2):139-43. PubMed ID: 26351870
[TBL] [Abstract][Full Text] [Related]
13. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R
Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
[TBL] [Abstract][Full Text] [Related]
14. An In Vivo Comparison of Hemostatic Gelatin Matrix Products in a Porcine Spleen Biopsy-punch Model.
Hutchinson RW; Werrlein S; Johns DB; Zhang G; Clymer JW; Kocharian R
Surg Technol Int; 2015 Nov; 27():53-7. PubMed ID: 26680379
[TBL] [Abstract][Full Text] [Related]
15. Choice of hemostatic agent and hospital length of stay in cardiovascular surgery.
Krishnan S; Conner TM; Leslie R; Stemkowski S; Shander A
Semin Cardiothorac Vasc Anesth; 2009 Dec; 13(4):225-30. PubMed ID: 19951982
[TBL] [Abstract][Full Text] [Related]
16. FLOSEAL Versus SURGIFLO in Lumbar Surgery: Similar Outcomes, Different Costs in a Matched Cohort Analysis.
Ye IB; Thomson AE; Smith RA; Pease TJ; Chowdhury N; Donahue J; Miseo V; Jauregui JJ; Cavanaugh DL; Koh EY; Ludwig SC
World Neurosurg; 2023 Jun; ():. PubMed ID: 37356481
[TBL] [Abstract][Full Text] [Related]
17. A Retrospective Analysis of the Hemostatic Effect of FloSeal in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy.
Martorana E; Ghaith A; Micali S; Pirola GM; De Carne C; Fidanza F; Bianchi G
Urol Int; 2016; 96(3):274-9. PubMed ID: 26890812
[TBL] [Abstract][Full Text] [Related]
18. Improvement of Perioperative Outcomes in Major Gynecological and Gynecologic-Oncological Surgery with Hemostatic Gelatin-Thrombin Matrix.
Watrowski R; Jäger C; Forster J
In Vivo; 2017; 31(2):251-258. PubMed ID: 28358708
[TBL] [Abstract][Full Text] [Related]
19. Cost-consequence analysis of a hemostatic matrix alone or in combination for spine surgery patients.
Ramirez MG; Niu X; Epstein J; Yang D
J Med Econ; 2018 Oct; 21(10):1041-1046. PubMed ID: 30112922
[TBL] [Abstract][Full Text] [Related]
20. Hemostatic efficacy of two topical adjunctive hemostats in a porcine spleen biopsy punch model of moderate bleeding.
MacDonald MH; Zhang G; Tasse L; Wang D; De Leon H; Kocharian R
J Mater Sci Mater Med; 2021 Sep; 32(10):127. PubMed ID: 34591193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
